Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	681,439 shs	N/A
ADVM Adverum Biotechnologies	$2.15 -7.3%	$2.60	$1.78 ▼ $10.14	$44.91M	0.71	268,907 shs	254,487 shs
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
INMB INmune Bio	$2.31 -56.7%	$7.42	$1.93 ▼ $11.64	$53.08M	1.55	701,631 shs	32.68 million shs
TCRX TScan Therapeutics	$1.45 +3.6%	$1.50	$1.02 ▼ $7.89	$82.06M	0.98	412,687 shs	433,858 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	+81.60%
ADVM Adverum Biotechnologies	0.00%	+3.11%	+4.98%	-46.91%	-66.18%
APTO Aptose Biosciences	0.00%	0.00%	0.00%	-45.71%	-92.49%
INMB INmune Bio	0.00%	-16.46%	-28.55%	-31.75%	-39.57%
TCRX TScan Therapeutics	0.00%	-2.78%	-2.44%	+1.45%	-76.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	4.2947 of 5 stars	3.4	3.0	0.0	4.8	1.7	2.5	0.6
APTO Aptose Biosciences	1.1847 of 5 stars	3.8	0.0	0.0	0.0	0.6	0.0	0.0
INMB INmune Bio	2.0321 of 5 stars	3.6	0.0	0.0	0.0	2.8	1.7	0.6
TCRX TScan Therapeutics	2.8837 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	1,006.98% Upside
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
INMB INmune Bio	3.17	Buy	$22.80	887.01% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	437.93% Upside

Current Analyst Ratings Breakdown

Latest ADVM, TCRX, ACHL, APTO, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ADVM Adverum Biotechnologies	$1M	44.91	N/A	N/A	$3.40 per share	0.63
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
INMB INmune Bio	$10K	5,308.38	N/A	N/A	$1.45 per share	1.59
TCRX TScan Therapeutics	$2.82M	29.10	N/A	N/A	$4.26 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	8/12/2025 (Estimated)
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-2,974.08%	-55.76%	-36.56%	8/11/2025 (Estimated)

Latest ADVM, TCRX, ACHL, APTO, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
ADVM Adverum Biotechnologies	N/A	3.57	3.57
APTO Aptose Biosciences	N/A	1.05	1.05
INMB INmune Bio	N/A	2.64	2.64
TCRX TScan Therapeutics	0.15	8.55	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
ADVM Adverum Biotechnologies	48.17%
APTO Aptose Biosciences	26.62%
INMB INmune Bio	12.72%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
ADVM Adverum Biotechnologies	6.00%
APTO Aptose Biosciences	1.33%
INMB INmune Bio	35.70%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable

ADVM, TCRX, ACHL, APTO, and INMB Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell

June 14, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

June 3, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

What Analysts Are Saying About TScan Therapeutics Stock

May 9, 2025 | nasdaq.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.comA

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%

April 8, 2025 | aaii.comA

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

TScan Therapeutics appoints Camiolo as SVP, Market Access

March 27, 2025 | markets.businessinsider.com

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

March 27, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%

March 18, 2025 | aaii.comA

TScan Therapeutics assumed with an Overweight at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones

March 14, 2025 | uk.investing.com

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

March 7, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, TCRX, ACHL, APTO, and INMB Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)

As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Adverum Biotechnologies NASDAQ:ADVM

$2.15 -0.17 (-7.33%)

As of 04:00 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

INmune Bio NASDAQ:INMB

$2.31 -3.02 (-56.66%)

As of 04:00 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

TScan Therapeutics NASDAQ:TCRX

$1.45 +0.05 (+3.57%)

As of 04:00 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time